Clinical Trial Update: Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating two doses of BI 1026706 on LEP measurements in UVB-irradiated skin of healthy male volunteers; completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthy

Drugs mentioned

• BI 1026706 (BI 1026706)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Healthy | Phase 1 | Status: COMPLETED | Results posted: 2019-07-05